These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25696573)

  • 21. Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT1 antagonist.
    Zoumpoulakis P; Grdadolnik SG; Matsoukas J; Mavromoustakos T
    J Pharm Biomed Anal; 2002 Apr; 28(1):125-35. PubMed ID: 11861115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroprotective effects of angiotensin receptor blockers.
    Villapol S; Saavedra JM
    Am J Hypertens; 2015 Mar; 28(3):289-99. PubMed ID: 25362113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal Delivery of AT1 Receptor Antagonists Reduce Blood Pressure and Reveal a Vasodilatory Effect on Kidney Blood Vessels.
    Michalatou M; Androutsou ME; Antonopoulos M; Vlahakos DV; Agelis G; Zulli A; Qaradakhi T; Mikkelsen K; Apostolopoulos V; Matsoukas J
    Curr Mol Pharmacol; 2018; 11(3):226-236. PubMed ID: 29676239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
    Haddad G; Amiri F; Garcia R
    Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
    Hakim A; Stanke-Labesque F; Hoffmann P; Sessa C; Caron F; Cracowski JL; Bessard G
    J Cardiovasc Pharmacol; 2003 Jul; 42(1):42-7. PubMed ID: 12827025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF].
    Vítovec J; Špinar J; Špinarová L
    Vnitr Lek; 2015 May; 61(5):470-4. PubMed ID: 26075858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The preclinical basis of the therapeutic evaluation of losartan.
    Timmermans PB; Wong PC; Chiu AT; Smith RD
    J Hypertens Suppl; 1995 Jul; 13(1):S1-13. PubMed ID: 18800450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding of valsartan to mammalian angiotensin AT1 receptors.
    de Gasparo M; Whitebread S
    Regul Pept; 1995 Nov; 59(3):303-11. PubMed ID: 8577935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock.
    Łukawski K; Janowska A; Jakubus T; Tochman-Gawda A; Czuczwar SJ
    Eur J Pharmacol; 2010 Aug; 640(1-3):172-7. PubMed ID: 20465998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450.
    Yang R; Luo Z; Liu Y; Sun M; Zheng L; Chen Y; Li Y; Wang H; Chen L; Wu M; Zhao H
    Curr Drug Metab; 2016; 17(7):681-91. PubMed ID: 27216792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
    Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
    Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
    J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan.
    Bhuiyan MA; Hossain M; Nakamura T; Ozaki M; Nagatomo T
    J Pharmacol Sci; 2010; 112(4):459-62. PubMed ID: 20308802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle.
    Simko F; Simko J; Fabryova M
    Cardiovasc Drugs Ther; 2003 May; 17(3):287-90. PubMed ID: 14669746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.
    Kalinowski L; Matys T; Chabielska E; Buczko W; Malinski T
    Hypertension; 2002 Oct; 40(4):521-7. PubMed ID: 12364357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain.
    Muders F; Palkovits M; Bahner U; Kirst I; Elsner D; Jandeleit-Dahm K
    Pharmacol Res; 2001 Mar; 43(3):251-5. PubMed ID: 11401417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative antihypertensive effects of angiotensin II receptor antagonists.
    Burnier M; Brunner HR
    J Am Soc Nephrol; 1999 Apr; 10 Suppl 12():S278-82. PubMed ID: 10201883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers.
    Imaizumi S; Miura S; Yahiro E; Uehara Y; Komuro I; Saku K
    Curr Pharm Des; 2013; 19(17):3002-8. PubMed ID: 23176212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
    Huber K; Pachinger O; Pichler M; Klein W
    Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.